Traumatic bleeding is an especially critical threat for our armed forces. Cayuga is working with DARPA and the US Army to test CAY001's potential as a battlefield drug. This has culminated in a:
DARPA grant to study CAY001 in a swine injury model
Phase I Army SBIR
Phase II Army SBIR (Ongoing)
FY20 Joint Warfighter Medical Research Grant
Combined, these grants have provided ~$3MM in non-dilutive funding to study CAY001's ability to treat traumatic hemorrhage.
Stopping blood loss on the battlefield is the most immediate problem for the injured warfighter. Non-compressible, e.g. abdominal, injuries remain “a clear and persistent gap in medical treatment capability” according to the US Army. Early treatment can mean the difference between life and death.
CAY001 is a shelf-stable drug designed to be deployed with first-responders such as medics and corpsmen directly at the point-of-care. Our goal is to safely promote clotting at the injury site in order to buy valuable time to evacuate wounded service-men and -women to a location where they can receive definitive surgical care.